- Successful Pre-Operative Local Control of Skin Invasion of Breast Cancer Using a Combination of Systemic Chemotherapy and Mohs Paste
-
Takeuchi M, Katsuki T, Yoshida K, Onoda M, Iwamura M, Inokuchi T, Furutani A, Katoh T, Kawano K, Hirata K
- KMID: 2522099
- J Breast Cancer.
- 2021 Oct;24(5):481-490.
- doi: 10.4048/jbc.2021.24.e46
Locally advanced breast cancer (tumor > 5 cm, widespread infiltration of the skin and muscle, or metastases to lymph nodes) is difficult to resect by surgery, and even when it... -
- CITED
-
- Close
- SHARE
-
- Close
- Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?
-
Kato J, Hiraoka S, Nakarai A, Takashima , Inokuchi T, Ichinose M
- KMID: 2174504
- Intest Res.
- 2016 Jan;14(1):5-14.
- doi: 10.5217/ir.2016.14.1.5
Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity,... -
- CITED
-
- Close
- SHARE
-
- Close
- Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis
-
Hiraoka S, Inokuchi T, Nakarai A, Takashima , Takei D, Sugihara Y, Takahara M, Harada K, Okada H, Kato J
- KMID: 2429068
- Gut Liver.
- 2018 Mar;12(2):142-148.
- doi: 10.5009/gnl17013
BACKGROUND/AIMS: Both fecal immunochemical test (FIT) and fecal calprotectin (Fcal) results are useful biomarkers for ulcerative colitis (UC). However, the situations in which each marker should be used are largely... -
- CITED
-
- Close
- SHARE
-
- Close
- An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
-
Nakarai A, Kato J, Hiraoka S, Takashima , Inokuchi T, Takahara M, Sugihara Y, Harada K, Okada H
- KMID: 2417308
- Gut Liver.
- 2018 Jul;12(4):420-425.
- doi: 10.5009/gnl17236
BACKGROUND/AIMS: Although mucosal healing (MH) has been considered a treatment goal for patients with ulcerative colitis (UC), the risk factors predictive of relapse in patients who achieve MH are unknown.... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
-
Hiraoka S, Takashima , Kondo Y, Inokuchi T, Sugihara Y, Takahara M, Kawano S, Harada K, Kato J, Okada H
- KMID: 2402650
- Intest Res.
- 2018 Jan;16(1):75-82.
- doi: 10.5217/ir.2018.16.1.75
BACKGROUND/AIMS: The efficacy of anti-tumor necrosis factor α (anti-TNFα) antibodies for postoperative Crohn's disease (CD) in patients who were treated with these agents prior to surgery is largely unknown. METHODS: CD... -
- CITED
-
- Close
- SHARE
-
- Close
- The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces
-
Hiraoka S, Takashima , Inokuchi T, Nakarai A, Takahara M, Harada K, Seki Y, Watanabe K, Kato J, Okada H
- KMID: 2449961
- Intest Res.
- 2019 Apr;17(2):202-209.
- doi: 10.5217/ir.2018.00086
BACKGROUND/AIMS: Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance... -
- CITED
-
- Close
- SHARE
-
- Close
- Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease
-
Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi , Oshita M, Tanaka H, Ozeki K, Takahashi , Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T
- KMID: 2434163
- Intest Res.
- 2018 Oct;16(4):609-618.
- doi: 10.5217/ir.2018.00044
BACKGROUND/AIMS: The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate... -
- CITED
-
- Close
- SHARE
-
- Close
